Moreover, an antibody-drug conjugate (ADC) targeting ENPP3 is undergoing phase II clinical trials for advanced renal cell carcinoma treatment [29], offering a promising therapeutic approach for EMs. This evidence concerns the gene ENPP3 and renal cell carcinoma.